Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | PON1 | P27169 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28988626 | 0.91 | ALDH1A1 (0.36) | ALDH1A1HPGDHSD17B10TDP1NPC1 | |
| SCHEMBL20932861 | 0.78 | CYP26B1 (0.36) | ALOX15NPC1RAB9A | |
| SCHEMBL2704179 | 0.77 | HPGD (0.43) | KIF11ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL26144298 | 0.77 | ALDH1A1 (0.40) | KIF11ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL17615540 | 0.77 | PTPN1 (0.47) | KIF11ALDH1A1PTPN1GAAMAPT | |
| SCHEMBL19620023 | 0.76 | ESR1 (0.34) | PTPN1 | |
| SCHEMBL23478670 | 0.75 | ALDH1A1 (0.44) | KIF11ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL13915050 | 0.75 | CYP11B1 (0.39) | ALDH1A1HPGDHSD17B10NPC1RAB9A | |
| SCHEMBL23422281 | 0.75 | KIF11 (0.40) | KIF11ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL23478525 | 0.75 | PON1 (0.36) | KIF11ALDH1A1HPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | KIF11 3117/4885ALDH1A1 4135/4885HPGD 1026/4885 |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | KIF11 1610/4885ALDH1A1 495/4885HPGD 741/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | KIF11 2189/4885ALDH1A1 477/4885HPGD 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.